Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 5/20 | 0.63 |
| ▸ | IDUA | P35475 | 1/20 | 0.47 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | PYGB | P11216 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9112754 | 1.00 | LGALS3 (0.63) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL5961308 | 1.00 | LGALS3 (0.63) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL8329271 | 1.00 | LGALS3 (0.63) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL5493000 | 1.00 | LGALS3 (0.63) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL8327423 | 1.00 | LGALS3 (0.63) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL1065038 | 1.00 | LGALS3 (0.63) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL2688569 | 1.00 | LGALS3 (0.63) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL2688005 | 0.98 | LGALS3 (0.60) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL8331451 | 0.98 | LGALS3 (0.60) | LGALS3IDUALGALS1LGALS9LGALS8 | |
| SCHEMBL6785168 | 0.98 | LGALS3 (0.60) | LGALS3IDUALGALS1LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869378-B | Compounds for preventing and treating diseases and uses thereof | 卡莱克汀科学有限责任公司 | 2023-10-13 | — | — | CN | disclosed |
| US-6958395-B2 | Method for producing water-soluble saccharide conjugates and saccharide mimetics by Diels-Alder reaction | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2005-10-25 | — | — | US | disclosed |
| US-20040059101-A1 | Method for producing water-soluble saccharide conjugates and saccharide mimetics by diels-alder reaction | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2004-03-25 | — | — | US | disclosed |
| US-6660720-B2 | Targeted oligonucleotide conjugates | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030130220-A1 | Targeted oligonucleotide conjugates | IONIS PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6525031-B2 | Complexes carry primary moieties, chiefly therapeutic, to target cells; feature cell surface receptor ligands to provide specificity; ligands are preferably bound to primary moieties through polyfunctional manifold compounds. | ISIS PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020058639-A1 | Targeted oligonucleotide conjugates | ISIS PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6300319-B1 | COMPLEX WITH MODULATION OF CELLS SURFACE RECEPTOR LIGANDS | ISIS PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | disclosed |
| WO-1999065925-A1 | TARGETED OLIGONUCLEOTIDE CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| US-5872111-A | TOILET BAR SOAP, FACIAL BODY CLEANSER, SHAMPOO, CONDITIONER, COSMETIC,SHAVING CREAM OR LOTION, SHOWER GEL, FABRIC SOFTENING CONDITIONER, AND UNDERARM DEODORANT/ANTI-PERSPIRANT | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0369182-B1 | Antitumour saccharide conjugates | DEUTSCHES KREBSFORSCH (DE) | 1995-03-29 | — | — | EP | disclosed |
| EP-0369182-A1 | Antitumour saccharide conjugates | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1990-05-23 | — | — | EP | disclosed |
| WO-1990004597-A1 | TUMOR-INHIBITING SACCHARIDE CONJUGATES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1990-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130220-A1 | Targeted oligonucleotide conjugates | CD47, CD44, FOLR1 | LGALS3 612/4885IDUA 2302/4885LGALS1 774/4885 |
| US-20040059101-A1 | Method for producing water-soluble saccharide conjugates and saccharide mimetics by diels-alder reaction | SI, MAN1B1, SORD | LGALS3 705/4885IDUA 46/4885LGALS1 551/4885 |
| US-20020058639-A1 | Targeted oligonucleotide conjugates | CD47, CD44, FOLR1 | LGALS3 612/4885IDUA 2302/4885LGALS1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.